CompletedNot Applicable

Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology

France30 participantsStarted 2020-06-23

Plain-language summary

Severe SARS-CoV-2 infection, responsible of COVID-19, is accompanied by many venous thromboembolic events. Antithrombotic treatment is the cornerstone of management of many neurovascular diseases (NVDs) and the benefit-risk ratio is crucial to avoid hemorrhagic complications. Therefore, in non-severe COVID-19 patients affected by NVDs, the diagnostic of deep venous thrombosis (DVT) is challenging. Using bedside Doppler ultrasonography (DUS) of lower limbs, this study investigated the rates of DVT in these patients in stroke unit.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

* Inclusion criteria: * Age\>18 years * COVID-19 confirmed with RT-PCER and/or chest CT-scan * Acute neurovascular disease defined as transient ischemic attack or acute ischemic stroke or venous cerebral thrombosis or hemorrhagic stroke. * Exclusion criteria: * age\<18 * Other neurovascular diseases

What they're measuring

Number of cumulated deep venous thrombosis among the hospitalization

Timeframe: Day 7 after admisssion

Trial details

NCT IDNCT04452422

SponsorUniversity Hospital, Strasbourg, France

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-09-23

View on ClinicalTrials.gov More Deep Venous Thrombosis trials